top of page
  • Completed

NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma

Updated: Sep 27, 2022

IFM2005-02

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

IFM2005-02

NCT00430365: Phase 3 - Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02):

Maintenance treatment of myeloma.


Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).


Sponsor

University Hospital, Toulouse


Collaborators

Intergroupe Francophone du Myelome

 

ClinicalTrials.gov Identifier: NCT00430365

First Posted : February 1, 2007

Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).

 
 

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma

NEJM; May 2012

 

Belgium

France

Switzerland


Posts Archive
bottom of page